Coherus BioSciences Partners with STORM Therapeutics on LOQTORZI/STC-15 Combination Study.
ByAinvest
Tuesday, May 27, 2025 8:36 am ET1min read
CHRS--
The Phase 1b study will enroll up to 188 patients in the United States, with the first patient already dosed. Coherus will provide LOQTORZI while STORM will sponsor the trial. Both companies retain commercial rights to their respective compounds. The study will initially focus on safety and efficacy in Phase 1b before expanding into multiple cancer types in Phase 2.
The collaboration is notable for its strategic alignment, with Coherus seeking to expand the indications for LOQTORZI beyond nasopharyngeal carcinoma (NPC) through cost-efficient drug supply agreements. The combination of STC-15 and LOQTORZI represents a novel approach to cancer treatment, potentially overcoming resistance mechanisms seen with PD-1 monotherapy.
This partnership underscores Coherus' commitment to advancing its pipeline and driving sales multiples and synergies through proprietary combinations. The company's immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses.
For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit [www.loqtorzi.com](http://www.loqtorzi.com).
References:
[1] https://www.stocktitan.net/news/CHRS/coherus-announces-clinical-collaboration-with-storm-therapeutics-to-xxpiwxdnmomm.html
Coherus BioSciences has partnered with STORM Therapeutics to evaluate the METTL3 inhibitor STC-15 in combination with Coherus' PD-1 inhibitor LOQTORZI for the treatment of non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma, and endometrial cancer. The Phase 1b/2 study aims to assess the safety and efficacy of the combination therapy.
Coherus BioSciences (NASDAQ: CHRS) has entered a clinical collaboration with STORM Therapeutics to evaluate the combination of STC-15, a METTL3 inhibitor, and LOQTORZI, Coherus' next-generation PD-1 inhibitor, in a Phase 1b/2 study targeting multiple cancer types. The study aims to assess the safety and efficacy of the combination therapy for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, and endometrial cancer.The Phase 1b study will enroll up to 188 patients in the United States, with the first patient already dosed. Coherus will provide LOQTORZI while STORM will sponsor the trial. Both companies retain commercial rights to their respective compounds. The study will initially focus on safety and efficacy in Phase 1b before expanding into multiple cancer types in Phase 2.
The collaboration is notable for its strategic alignment, with Coherus seeking to expand the indications for LOQTORZI beyond nasopharyngeal carcinoma (NPC) through cost-efficient drug supply agreements. The combination of STC-15 and LOQTORZI represents a novel approach to cancer treatment, potentially overcoming resistance mechanisms seen with PD-1 monotherapy.
This partnership underscores Coherus' commitment to advancing its pipeline and driving sales multiples and synergies through proprietary combinations. The company's immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses.
For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit [www.loqtorzi.com](http://www.loqtorzi.com).
References:
[1] https://www.stocktitan.net/news/CHRS/coherus-announces-clinical-collaboration-with-storm-therapeutics-to-xxpiwxdnmomm.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet